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ess: amer.alhasani@roySummary In addition to breathlessness and cough, excessive mucus production is
one of the main symptoms of chronic obstructive pulmonary disease (COPD). Excess
mucus coupled with deteriorating mucociliary clearance is associated with a decline
in lung function and an increased risk of death from pulmonary infection. The effect
of ViozanTM (Sibenadet HCI, AR-C68397AA), a novel dual D2 dopamine receptor, b2-
adrenoceptor agonist, on mucociliary clearance was investigated together with that
of a b2-adrenoceptor agonist, salbutamol. Using a double blind, parallel group study
design, 15 patients with COPD, all habitual smokers, were randomised to receive
nebulised sidenadet (3mg tid; n ¼ 7) or salbutamol (5mg tid; n ¼ 8) for 10 days.
Lung mucociliary clearance rates were measured, by a standard radioaerosol
technique, before and after the treatment period, as were 24-h sputum volumes.
Both sibenadet and salbutamol therapies resulted in significant ðPo0:02Þ enhance-
ment of lung mucociliary clearance. The 24-h sputum volume was significantly
reduced following sibenadet therapy ðPo0:03Þ whereas salbutamol therapy had no
effect. Our results, in addition to illustrating the effects of a standard b2 agonist on
mucociliary clearance, strongly suggest the potential dual benefit of dual-agonist
compounds in lessening sputum production whilst simultaneously enhancing
mucociliary clearance. For reasons unconnected with the present study, develop-
ment work on this specific formulation is no longer proceeding.
r 2004 Elsevier Ltd. All rights reserved.4 Elsevier Ltd. All rights reserv
7-7940500; fax: +44-207-
alfree.nhs.uk (A. Hasani).Introduction
Along with breathlessness and cough, excessive
mucus production is one of the key symptoms of
chronic obstructive pulmonary disease (COPD).
Once thought to be a benign symptom, mucused.
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ciated with an accelerated decline in forced
expiratory volume in 1 s ðFEV1Þ and an increased
risk of death from pulmonary infection.1,2
Mucociliary clearance is a vital host defence
mechanism of the airways which, together with
clearance by cough, helps to keep the lungs free of
inhaled particles and materials as well as locally
produced biological debris.3,4 Deterioration of lung
mucociliary clearance as occurs in COPD5,6 results
in the loss of the protective role of ciliated
epithelium and contributes to the pathophysiology
of the disease.7
COPD is a chronic irreversible disorder of the
airways for which no current therapy can yet
provide adequate relief. Treatment regimens rely
on the use of bronchodilators, which offer
some relief from breathlessness but have little
effect on other key symptoms.8 Sibenadet was
developed as a novel dual D2 dopamine receptor,
b2-adrenoceptor agonist in order to combine the
bronchodilator activity of a b2-adrenoceptor
agonist with the novel sensory afferent nerve
modulating effects associated with D2-receptor
agonism.9 Until recently this agent was
under development specifically to treat the key
symptoms of COPD: breathlessness, cough and
sputum. For reasons unconnected with the
present study, development work on this specific
formulation is no longer proceeding—but the
potential value of D2 receptor agonist therapy
(alone or in combination with b2 agonist
therapy) strongly implies that the search for
effective forms of D2 receptor agonist medication
should continue.
The effect of the D2 receptor agonist activity of
AR-C68397AA on ammonia-stimulated reflex mucus
production has been demonstrated in anaesthe-
tized, ventilated, b-blocked dogs.10,11 Sibenadet
therapy inhibited this reflex mucus secretion to the
same extent as vagal cooling ( 70% inhibition) and
this effect was fully reversed by the peripherally
acting dopamine antagonist domperidone.11 Inhibi-
tion of reflex mucus secretion was not observed
with the administration of either salmeterol or
ipratropium bromide.
Given the problems COPD patients experience
from excessive mucus production, these data argue
a need for evidence on how a D2=b2 agonist may
effect mucus production and retention in patients
significantly handicapped with COPD symptoms. We
therefore investigated the effects of sibenadet (as
a trial example of a D2=b2 agonist) and of
salbutamol (as an example of a well-established
b2 agonist) on mucociliary clearance and sputum
production in patients with COPD.Methods
Patients
Male and female adult smokers with COPD (aged
45–75 years) were enrolled into the study. Inclusion
criteria were: clinical diagnosis of COPD defined as
a disorder characterized by reduced peak expira-
tory flow (PEF) and the slow forced emptying of the
lungs; COPD symptoms for42 years; reversibility in
FEV1o15% and o200ml following inhalation of
200mg salbutamol (via a pressurized metered dose
inhaler); FEV1 to forced vital capacity (FVC) ratio
o70% at screening; and FEV1 10–70% of predicted
normal at screening. In addition, female patients
had to be surgically sterile or post-menopausal. All
patients were current smokers with a history of at
least 5 pack years and produced X15ml sputum
volume per day.
Patients were excluded for the following reasons:
history of alcohol or drug abuse or any conditions
associated with poor compliance; a requirement for
domiciliary oxygen; significant cardiovascular, re-
nal, endocrinological, neurological or liver disease,
or malignancy (past or present); myocardial infarc-
tion within the previous 6 months. Patients were
not eligible for the study if they had any significant
clinical chemistry, hematological or electrocardio-
gram abnormalities; impairment of heart function;
COPD exacerbation requiring hospitalization, a
course of antibiotics or a change in oral/inhaled
corticosteroid dosage, in the previous 6 weeks; or a
history of asthma, bronchiectasis or cystic fibrosis.Study design
This was a single-centre, double blind, and parallel
group study. Eligible patients entered a baseline
period (10 days) when lung function and baseline
characteristics were assessed. At visit 2, patients
were randomized to receive either sibenadet ð3mgÞ
or salbutamol (5mg) for 10 days, administered as
nebulized 4ml solutions taken three times daily.
The 5mg salbutamol dose was selected because it
aimed to provide comparable b2-adrenoceptor
agonist activity to sibenadet. Blinding was achieved
by providing clear solutions in matched pre-coded
vials.
Throughout the study, patients completed a daily
diary card to record sputum production, intake of
all medications and any adverse events. Compli-
ance was assessed from diary cards and number of
treatment vials being used.
Patients were allowed to continue with their
regular COPD medication, with the exception of:
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receptor agonists or antagonists, anti-tussives or
proprietary medicines aimed at reducing sputum
and/or cough, and antibiotics. Short-acting b2-
adrenoceptor agonists were allowed as rescue
medication only during the treatment phase and
use was recorded in the diary card and the case
report form.
The study was approved by the Ethics Committee
of the Royal Free Hospital and all patients gave
informed written consent.Mucociliary clearance
Mucociliary clearance was analysed in terms of
time profiles for the retention of radioaerosol
particles measured as the number of counts
detected in the tracheobronchial system corrected
for sputum removed by productive cough.
A non-invasive radioaerosol technique12 was used
to provide objective measurements of lung muco-
ciliary clearance at visit 2, before the first dose of
treatment and at visit 4, immediately following the
last dose of treatment. Patients were not allowed
to smoke at least 1 h before radioaerosol adminis-
tration, nor in the following 6 h. Patients wore a
nose-clip and from a seated position inhaled,
through a mouthpiece, polystyrene particles of
5mm diameter, which had been labelled with the
gamma-emitting radionuclide 99mTc: This was gen-
erated using a spinning top generator within an
airtight tank.13 Inhalation involved taking discrete
breaths (0.45 l) from resting level of the lungs,
followed by a 3-second breath-hold to enhance, by
sedimentation, peripheral deposition of the radio-
aerosol particles within the lungs.14
Initial radioaerosol particles deposition in the
lung and its subsequent clearance were measured
by two axially opposed scintillation detectors
placed midway down the sternum and anteropos-
teriorly to the chest.15 The collimated detectors
measured the gamma-radiation emitted by these
particles, from most of both lungs, and counts were
recorded after the inhalation of particles at 30-min
intervals up to 6 h and then at 24 h. The residual
radioaerosol particles in the lungs at 24 h was used
to estimate alveolar deposition, which was taken as
the proportion of particles deposited beyond
ciliated airways and therefore not available for
mucociliary clearance.16
A tracheobronchial retention curve was gener-
ated by the subtraction of the alveolar deposition
from the total lung burden.17 Tracheobronchial
clearance was assessed by measuring the area
under the curve18 for the first 3 h ðAUC023 hÞ; thesecond 3 h ðAUC326 hÞ and for the entire 6-h
observation period ðAUC026hÞ: During the 6-h
observation period, all coughs were recorded, and
any sputum collected was weighed and its radio-
active content determined and expressed as a
percentage of the initial tracheobronchial deposi-
tion. This percentage was added back to the
retention curves to account for the effect of
productive coughing on mucus transport.19
Sputum volume
Sputum was collected over a 24-h period by each
patient before visits 2 and 4 and the volume and
appearance were recorded. Patients also esti-
mated, and recorded in their diary card, the
approximate volume of sputum produced daily
using the following 6-point scale based on the
collection vessel: 0 ¼ no sputum; 1 ¼ a teaspoon
ðp5mlÞ; 2 ¼ a tablespoon ðp10mlÞ; 3 ¼ an egg cup
ðp30mlÞ; 4 ¼ half a cup ðp50mlÞ and 5 ¼ a cup
ð450mlÞ:
Safety and tolerance
Lung function testing (FEV1 and FVC) was measured
for each patient at visits 1, 2, 3, and 4 using a
compact spirometer (Vitalograph, Buckingham,
UK).
Routine clinical chemistry, hematology and ur-
inalysis tests were performed at screening (visit 1)
and at the end of the treatment period (visit 4).
At visits 1, 3 (interim visit) and 4 a physical
examination was performed.
All adverse events were documented on the
patients case report form. All adverse events were
monitored until resolved.
Statistical analysis
The data were not normally distributed, and
statistical analysis was assessed using the nonpara-
metric paired and unpaired Wilcoxon test. GB-STAT
software (Dynamic Microsystems, Inc. Silver Spring,
MD) was used for that purpose. The level of
significance was taken at Po0:05: Results are
expressed as meanSE.Results
Patient demographics
Fifteen patients were randomized, of whom 14
completed the study. One patient, from the
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Table 1 Patients characteristics and baseline lung function.
Characteristic Sibenadet Salbutamol
ðn ¼ 7Þ ðn ¼ 7Þ
Sex 5M,2F 5M,2F
Age (years) 64 1 65 2
Smoking (pack years) 41 5 44 6
FEV1 (l) 0:80 0:08 1:27 0:21
30 2 %Predicted 47 6 %Predicted
FVC (l) 1:89 0:34 2:68 0:33
55 7 %Predicted 80 9 %Predicted
Figure 1 Mean tracheobronchial retention curves for the two groups of patients who were treated with either
sibenadet or salbutamol.
A. Hasani et al.148salbutamol group, discontinued after receiving
treatment for 6 days because of an adverse event,
dizziness. The two treatment groups had well-
matched demographics and baseline characteristics
(Table 1) with the exception of FEV1 and FVC, which
were lower in the sibenadet group.
Both treatment groups recorded good compli-
ance of 93%. Patients in both groups reported
taking a mean of 28 doses (range: 26–30 doses of
sibenadet vs 25–30 doses of salbutamol).Mucociliary clearance
Alveolar deposition for the pre- and post-treatment
visits was 25 5 vs 27 5; respectively, for the
sibenadet group and 26 4 vs 32 3; respectively,
for the salbutamol group. There were no significant
differences within and between the two groups.Following 10 days of treatment the number of
coughs was very slightly (non-significantly) re-
duced. During the 6-h observation period the
measured number of coughs changed from 15 3
to 14 5 in the sibenadet group and from 24 14
to 21 14 in the salbutamol group.
Fig. 1 shows the mean tracheobronchial reten-
tion curves, corrected for productive coughing, for
the sibenadet and salbutamol groups at pre- and
post-treatment. Pre-treatment tracheobronchial
clearance was on average, but not statistically so,
slower in the group who were subsequently treated
with sibenadet compared with the group who were
treated with salbutamol.
Both treatments resulted in significant en-
hancement of clearance. The area under the
tracheobronchial retention curve for the sibe-
nadet and salbutamol groups over the first 3 h,
the second 3 h, and the whole 6 h observation
periods were given in Table 2. After treatment the
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Table 2 Area under tracheobronchial retention curve (%h) for two groups of COPD patients treated with
sibenadet and salbutamol.
AUC Sibenadet Salbutamol
Pre Post P Pre Post P
0–3 248 16 234 16 o0:10 235 12 206 18 o0:02
3–6 210 19 155 15 o0:02 170 24 115 26 o0:03
0–6 458 34 389 29 o0:02 405 35 321 43 o0:02
Effect of viozan and salbutamol on mucociliary clearance 149AUC023;AUC326;AUC026 for both groups were
smaller (i.e. faster clearance) compared to their
respective pre-treatment AUC.
Sputum volume
Fig. 2 shows the 24-h sputum volume produced by
each patient before and after treatment with
sibenadet (a) and salbutamol (b). In the sibenadet
group the 24-h sputum volume was significantly
ðPo0:03Þ reduced following treatment (25 4 vs
17 3ml) whereas very small change occurred in
the salbutamol group (26 7 vs 25 8ml). Sputum
volume data held on the patient diary cards showed
that at baseline, in both sibenadet and salbutamol
groups, patients recorded mean sputum volumes of
p30ml pre-treatment compared withp15ml post-
treatment. Sputum appearance did not alter upon
treatment with sibenadet but in the salbutamol
group it changed from predominantly clear to
white.Figure 2 Mean sputum volume produced by each patient
during 6-h observation period at baseline and at treat-
ment with sibenadet (a) and salbutamol (b).Safety
At all visits FEV1 and FVC values were lower but not
significant in the sibenadet group compared with
the salbutamol group, which may suggest that
patients who received sibenadet may have had
more severe COPD.
Two patients, both receiving salbutamol, had
clinically significant changes in laboratory data
(slightly increased urea value and increased white
blood cell count, both recorded after treatment).
These readings were not considered likely to be
related to treatment.
Sibenadet and salbutamol were equally well
tolerated by patients with COPD. Three patients
from each group reported at least one adverse
event during treatment. Adverse events considered
possibly related to treatment included dizziness
and pharyngitis for salbutamol. For sibenadet, such
adverse events included dizziness, feeling warm,and constipation. No deaths or serious adverse
events were reported during the study and only one
patient, a 70-year-old man receiving salbutamol,
discontinued treatment as a result of dizziness
after the sixth day of treatment.
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The rate of tracheobronchial clearance of depos-
ited radioaerosol particles depends on the site
of their initial deposition within the lung.14 In this
study alveolar deposition for pre- and post-
treatment in both sibenadet and salbutamol groups
was similar. Thus the proportions of radio-
aerosol particles available for clearance by mucus
transport were similar and direct comparison
of rates of tracheobronchial clearance is appro-
priate.
Tracheobronchial clearance principally comprises
lung mucociliary clearance and cough. Tracheo-
bronchial clearance curve was suitably corrected
for the productive coughing; thereby the curves
reflected clearance predominantly due to muco-
ciliary transport. Unproductive coughing, however,
is known to result in a proximal shift of secretions
within the human lung.20 The contribution of cough
in this study is small and similar between pre and
post treatment of both groups. Therefore, the
measured tracheobronchial clearance was mainly a
reflection of mucociliary clearance.4
The AUC was used as an index of tracheo-
bronchial clearance as it reflects clearance
over an observation period and avoids multiple
statistical testing at numerous time points.
This study has shown that sibenadet and salbutamol
significantly improved mucociliary clearance
with similar efficacy. However, there were
minor differences in the time-course of the effect
of sibenadet and salbutamol. Sibenadet therapy
appeared more effective during the last 3 h of
observation period whereas salbutamol therapy
was significantly effective during the first 3 h.
Salbutamol has been shown to enhance lung
mucociliary clearance rates in chronic bronchitis
when given topically from a metered dose inhaler,
albeit at 2.5 times the normal recommended
dose.21 In asthma, minimum clearance rates were
achieved with salbutamol, 8mg twice daily, com-
pared with theophylline and placebo.22 The b2-
adrenoceptor agonist properties of sibenadet have
been directly compared with salbutamol, salme-
terol and formoterol in vitro using guinea
pig superfused trachea and in vivo in guinea pig
and dog aerosol studies.23 These animal studies
showed that sibenadet had comparable or more
potent b2-agonist activity than these commonly
used bronchodilators. This has been substantiated
by findings from this human investigation, which
showed that sibenadet and salbutamol had similar
effects on mucociliary clearance.
The mean 24-h sputum volume was significantly
lower in the sibenadet group than in the salbutamolgroup. Subjective estimates of sputum volume in
patient diary cards showed no differences between
treatment groups. Since there was no impairment
of mucociliary clearance by sibenadet, the reduc-
tion in 24-h sputum volume may be related to a
reduction in sputum production, produced via a D2-
receptor mediated effect.
Interestingly, the baseline demographic data
indicated that patients in the sibenadet group had
poorer lung function demonstrated by lower FEV1
and FVC values than those patients in the salbuta-
mol group. This might suggest that patients treated
with sibenadet had more severe COPD than those in
the salbutamol group and may therefore account
for why the effects of sibenadet on FEV1 seemed
small. The severity of the disease in the sibenadet
group was reflected by a higher degree of impair-
ment of mucociliary clearance at baseline com-
pared to those in the salbutamol group. Thus,
sibenadet therapy could have been more effica-
cious than salbutamol therapy if the baseline
mucociliary clearance was the same.
Sibenadet and salbutamol were well tolerated.
Few adverse events were reported and no parti-
cular pattern of events was evident.
In conclusion, sibenadet, a novel, dual D2
dopamine receptor, b2-adrenoceptor agonist, has
been shown to significantly enhance mucociliary
clearance. These data suggest that sibenadet;
possibly by acting at D2 receptors, have the
potential to reduce sputum in patients with COPD.
This study is also the first to report that nebulized
salbutamol significantly improved mucociliary
clearance in patients with COPD.Acknowledgements
We thank the volunteer patients for participating in
the study and AstraZeneca for supplying the drugs
and for financial support.References
1. Vestbo J, Prescott E, Lang P. Association of chronic mucus
hypersecretion with FEV1 decline and chronic obstructive
pulmonary disease morbidity. Copenhagen City Heart Study
Group. Am J Respir Crit Care Med 1996;153:1530–5.
2. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion
in COPD and death from pulmonary infection. Eur Respir J
1995;8:1333–8.
3. Wanner A, Salathe M, O’Riordan TG. Mucociliary clearance in
the airways. Am J Respir Crit Care Med 1996;154:1868–902.
4. Hasani A, Agnew JE. The role of cough on mucociliary
clearance measurements. in: Salathe M, editor. Cilia and
mucus. New York: Dekker; 2001. p. 399–405.
ARTICLE IN PRESS
Effect of viozan and salbutamol on mucociliary clearance 1515. Puchelle E, Zahm JM, Girard F, et al. Mucociliary transport in
vivo and in vitro. Relations to sputum properties in chronic
bronchitis. Eur J Respir Dis 1980;61:254–64.
6. Smaldone GC, Foster WM, O’Riordan TG, et al. Regional
impairment of mucociliary clearance in chronic obstructive
pulmonary disease. Chest 1993;103:1390–6.
7. Hasani A, Pavia D, Rotondetto S, et al. Effect of oral
antibiotics on lung mucociliary clearance during exacerba-
tion of chronic obstructive pulmonary disease. Respir Med
1998;92:442–7.
8. Anthionsen NR, Connett JE, Kiley JP, et al. Effects of
smoking intervention and the use of an inhaled antic-
holinergic bronchodilator on the rate of decline of FEV1:
JAMA 1994;272:1497–505.
9. Mohammed S, Young A. Clinical aspects and treatment of
chronic obstructive pulmonary disease. Curr Opin Anti-
lnflam Immunomod Investig Drugs 1999;1:21–8.
10. Young A, Blackham A, Taylor, CV, et al. Reflex mucus
production in the anaesthetised dog. Eur Respir J 1998;12
(Suppl. 29):66s
11. Young A, Dougall IG, Blackham A, et al. ViozanTM; a novel
dual D2-receptor and b2-adrenoceptor agonist, inhibits
clinically relevant parameters in animal models of airways
disease. Am J Resp Crit Care Med 2000;161(Suppl.):
A820.
12. Pavia D, Sutton PP, Agnew JE, et al. Measurement of
bronchial mucociliary clearance. Eur J Respir Dis
1983;64(Suppl. 127):41–56.
13. Hasani A, Spiteri M, Pavia D, et al. Tracheobronchial
clearance in patients with pulmonary sarcoidosis. Chest
1992;101:1614–8.14. Agnew JE. Physical properties and mechanisms of deposition
of aerosols. in: Clarke SW, Pavia D, editors. Aerosols and the
lung. London: Butterworths; 1984. p. 44–70.
15. Hasani A, Pavia D, Spiteri MA, et al. Inhaled frusemide does
not affect lung mucociliary clearance in healthy and
asthmatic subjects. Eur Respir J 1994;7:1497–500
16. Bennett WD, Chapman WF, Lay JC, et al. Pulmonary
clearance of inhaled particles 24 to 48 hours post deposi-
tion. J Aerosol Med 1993;6:53–62.
17. Hasani A, Johnson M, Pavia D, et al. Impairment of lung
mucociliary clearance in pigeon fanciers. Chest 1992;102:
887–91.
18. Hasani A, Spiteri MA, Pavia D, et al. Effect of temazepam on
tracheobronchial mucus clearance. Thorax 1992;47:298–300
19. Hasani A, Pavia D. Cough as a clearance mechanism. in:
Braga PC, Allegra L, editors. Cough. New York: Raven Press;
1989. p. 52–87.
20. Hasani A, Pavia D, Agnew JE, et al. Regional mucus transport
following unproductive cough and forced expiration techni-
que in patients with airways obstruction. Chest
1994;105:1420–425
21. Fazio A, Lafortuna C. Effect of inhaled salbutamol on
mucociliary clearance in patients with chronic bronchitis.
Chest 1981;80:827–830
22. Hasani A, Agnew JE, Pavia D, et al. Effect of oral
bronchodilators on lung mucociliary clearance during sleep
in patients with asthma. Thorax 1993;48:287–289
23. Mohammed SP, Dougall IG, Taylor CV, et al. The b2-
adrenoceptor activity and duration of action of AR-
C68397AA: an in vitro and in vivo comparison. Am J Respir
Crit Care Med 1999;159(Suppl. 3):A813.
